KET-RO Plus RO DBT for Treatment Resistant Depression

计划入组 16 人 · 首次发布于 2023 年 11 月 18 日

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

计划入组 12 人 · 首次发布于 2008 年 3 月 6 日

Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

计划入组 190 人 · 首次发布于 2003 年 4 月 1 日

Mefloquine

C₁₇H₁₆F₆N₂O

LNP-599

SC-599

RIMA OBEID

Australia

Gradalis, Inc.

United States

FUNDACAO PIO XII

Brazil

Angelini Pharma Secures Exclusive Option for Sovargen's Novel Brain Health Asset SVG105

Genentech Advances RO-7759065 Development for Metastatic Solid Tumors

Cancer Monoclonal Antibody Partnerships Surge with 599 Deals Recorded Since 2016